. The annual growth of vaccine production output from 2007 to 2011 was 5.9%. Domestic vaccine production output between 2009 and 2010 was high er than that in 2007, 2008 , and 2011. Most currently, vaccine production output in 2011 was 392.2 billion KRW, indicating 2.83% of completed drug production output and 13 trillion 880.8 billion KRW [3] .
In other words, vaccines are not only identified as one of the most important items but also judged as items with the possibility of future development. Therefore, it is necessary to identify the overall economic scale of vaccines in the past five years in Korea, which can be an important indicator that pro vides background information in practical use.
This study tried to build basic information related to future production and sales of human vaccines in Korea by conduct ing research: 1) among domestic industries, with respect to the scale and trend of the drug production industry market produced by pharmaceutical industries in Korea, 2) on the portion of human vaccines, the amount of vaccine produc tion, and the marketing scale of the actual output by the func tional agent in the middle classification, 3) on sales of each major item of vaccines, 4) on the current situation of vaccine industry growth by sales of each treatment fields, and 5) on the portion of market and development situations of vaccines depending on its products.
Materials and Methods
Information about the national population in Korea, GNI, and GDP was obtained from the Economic Statistics System of the Bank of Korea [1] . Market situation of the drug indus try, actual output of nonprescription and prescription drugs (current situation), actual output by drug industry classifica tion, complete preparated drug records by drug industry func tional agent, production output by functional agent in the medium classification (current situation), and the number of items of medicalpharmaceutical industry complete prepa rated drugs (nonprescription and prescription) were identi fied based on the statistical data from the 2012 Korea Phar maceutical Industry Survey Report and Korea Health Indus try Statistics System (KHISS) provided by Korea Health In dustry Development Institute (KHIDI) [3, 4] , 2012 drug indus try analysis report (published in December 2012) by KHIDI, domestic pharmaceutical industry statistics published by Ko rea Pharmaceutical Manufacturers Association [2], the actual exports of drugs from Korea Pharmaceutical Traders Associa tion [5] , etc. Information including the domestic market scale of vaccines, trade balance of vaccines, market portion and development situations depending on vaccine products, do mestic major vaccine production companies, etc. were ob tained from the monthly report, "Health Industry Trend" published by KHIDI [6] . Additionally, Newsletter for the Na tional Immunization Program of Korea Centers for Disease Control and Prevention [7] provided information related to the current situation of essential vaccines in Korea. Table 1 shows the trend in the medicalpharmaceutical in dustry in Korea [26] . The whole market scale (production + import − export) was 15 trillion 62. Actual output of the medical-pharmaceutical product industry by classification (production output)
Results

Drug industry trend (current situation) in Korea
Regarding the medicalpharmaceutical product industry mar ket scale and current situations in Korea mentioned earlier, the actual output of the medicalpharmaceutical product in dustry depending on the classification is shown in 
Production of prescription drugs
When complete preparated drugs were divided into nonpre scription drugs and prescription drugs in 2011, the number of prescription drugs was 9,704 and these drugs produced 11 trillion 329 billion KRW; this showed that the number of items increased by 3.7%, but the production output decreased by 1.6%. While the portion of prescription drugs increased an nually from 76.8% in 2007 to 82.0% in 2010, it showed 81.6% in 2011 decreasing by 0.4% compared to the previous year. Although the portion of the produced prescription drugs de creased compared to the previous year, it still had a high per centage of more than 80% (Table 3) [2, 3] .
Market scale of vaccines in Korea (estimates of Korea Centers for Disease Control and Prevention)
The market scale of vaccines based on the estimates of Korea Centers for Disease Control and Preventions was about 710 billion in 2011 and showed an annual average growth of 11% in the past 6 years. This was equivalent to about 2% of the vaccine market in the world (Table 4) [6, 7] . In the portion of the amount of essential vaccines, the rate decreased from 68% in 2006 to 44% in 2011, but the amount of market scale increas ed from 289.1 billion KRW in 2006 to 308.9 billion in 2011, and the annual average growth rate was 1%. On the other hand, the rate of other vaccines increased from 32% in 2006 to 56% in 2011; the expenses also clearly increased from 133.9 Medical-pharmaceutical product: completely preparated drugs, narcotics, ultra-narcotics, psycotropic drugs, and drug substance (except quasi-drugs).
b)
Trade balance: export-import.
c)
Market scale: production − export + import. 
Portion of production output and vaccines of complete preparated drug in high ranking functional agents (in small classification)
The production output of complete preparated drugs in high ranking functional agents is shown in In 2011, the production output of vaccines was 392.2 bil lion which was 2.83% of the complete preparated drug pro duction output, 13 trillion 880.8 billion which was 2.54% of the drug production output, and 15 trillion 440.3 billion (unit: KRW) ( Table 5) .
Market portion by vaccine products in 2011
The size of the Korean vaccine market is classified as vaccines included in national immunization program (13 kinds) and other preventive vaccines. Subcategories such as amount of vaccine supply (production + import), market portion, stan dard amount (production cost, import cost) and market por tion are shown in Table 6 [6] .
In the supply (production + import) scale of vaccines mar ket scale by products in Korea in 2011, among 13 essential vaccines, hepatitis B was 399.8 billion, varicella was 68.6 bil lion, Japanese encephalitis (inactivated) was 163.2 billion, in tradermal Bacillus CalmetteGuérin (BCG) was 3.7 billion, diphtheria, tetanus and pertusiss (DTaP) was 246.3 billion, adult diphtheria/tetanus (Td) was 53.6 billion, adult diphthe ria/tetanus (Tdap) was 15.1 billion, inactivated poliovirus vaccine was 152.1 billion, DTapinactivated poliovirus vac cine was 33.2 billion, measles, mumps, rubella (MMR) was 120.5 billion, hemorrhagic fever with renal syndrome was 62.1 billion, typhoid fever was 16.4 billion, and influenza was 2.04 trillion. Regarding the other 10 types of vaccinations, He- [3] , and Korea Health Industry Statistics System, and Korea Health Industry Development Institute [4] . Values are presented as billion KRW or %. Note: Proportion of prescription drugs = production output of prescription drugs/(production output of non-prescription drugs+production output of prescription drugs)× 100. 
Major vaccine production companies in the nation (Korea)
Major vaccine manufacturing companies classified as do mestic and foreign (multinational, Japan, China) are listed in Table 7 [6].
Trade balance of vaccine types in Korea
The domestic vaccines market has been led by expensive im ported vaccines such as human papillomavirus vaccine, pneu mococcal vaccine, and other expensive preventivevaccines. Although the portion of other preventivevaccines was only 20% in the entire vaccines market, it accounted for 56% of the total amount, and the growth rate of preventivevaccines from 2006 to 2011 showed a 24% increase in the national qualifica tion amount. On the other hand, while the portion of essen tial vaccines is 80% of the entire vaccine usage, it accounted for 44% of the total amount, and the annual average growth rate was only 1%. Accordingly, the vaccine trade deficit was approximately $90 million in 2010 and then increased to ap proximately $120 million in 2011 (Table 8 ) [6] .
Vaccine development in Korea
Currently, SK Chemicals, Green Cross, LG Life Sciences, Bo ryeong Biopharma, etc. have led the development of vaccines in Korea. and IlYang Pharm.Co., Ltd., and Chong Kun Dang Pharmaceutical Corps. are also participating in the vaccine development (Table 6 ) [6] . However, the investment in re search and development is 61 billion KRW/yr, which is signif icantly low investment, compared to the average investment 
Discussion
In 2011, the production output of medicalpharmaceutical products was 15 trillion 440.3 billion KRW, and the market scale was 18 trillion 908.4 billion. The production output change by year increased by 5.9% from 2007 to 2011. In the portion of pharmaceutical industries among domestic indus tries in 2009, gross domestic product (GDP) was 10.63 trillion KRW, and manufacturer GDP was 2.657 trillion KRW; the amount of gross medicalpharmaceutical production in Korea (everything below: completed + drug substances, quasidrugs excluded) was 15 trillion 819.6 billion KRW which comprise 1.49% of total GDP and 5.95% of manufacturing GDP [26] . The production output of complete preparated drugs was 13 trillion 880.8 billion in 2011. When dividing complete pre parated drugs into nonprescription drugs and prescription drugs, the production output of nonprescription drugs was 2 trillion 552 billion and the production output of prescription drugs was 11 trillion 329 billion in 2011 [2, 3] .
The upper 30 functional agents (in a small classification) were 81.4% of the production output of complete preparated drugs. Vaccines (Classification number 631) were ranked 10th among the top 30 functional agents, and the production output was 227 in 2007, 309.6 in 2008, 537.6 in 2009, 596.1 in 2010, and 392.2 in 2011 (unit: billion KRW). The five year av erage growth rate was 14.7%. Vaccine production output in 2011 was 392.2 billion KRW, comprising a preparated drug production output of 2.83%, (13 trillion 880.8 billion KRW) and a medicalpharmaceutical product output of 2.54% (15 trillion 440.3 billion KRW) [2, 3] .
The market scale of vaccines in Korea was 710 billion in 2011, indicating an annual average growth rate of 11% in the past 6 years. This also indicates about 2% of the vaccine mar ket throughout the world. There was a significant increase in which the market scale of essential vaccines was 308.9 billion in 2011 and the cost of other vaccines was 399.8 billion in 2011 [6, 7] .
The domestic vaccine market has been led by expensive imported vaccines such as human papillomavirus vaccine and pneumococcal vaccine as well as other expensive pre ventivevaccines. Although the portion of other preventive vaccines was only 20% in the entire vaccine market, it account ed for 56% of the total amount, and the growth rate of preven tivevaccines from 2006 to 2011 was 24% of the national qual ification amount. The vaccine trade deficit in 2011 increased to approximately $120 million. Investment in research and development is in a significantly low level at 61 billion KRW/ yr, compared to the average investment (160650 billion KRW) of the premium vaccine development of multinational pharmaceutical companies [6] .
Park [6] , who analyzed the reality of Korea above, suggest ed that 1) safety enhancement of citizens through establish ment of vaccine independency, 2) decrease of medical cost and consolidation of health insurance finance through pre ventive vaccination, 3) developing high value added vaccine industry, and 4) therapeutic vaccines armed with new high technology [6] . There are four factors that should be over come by the Korea vaccine industry: 1) Improvement of do mestic market reduction because of low birthrate and high dependence on imports, 2) development of technology im provement which leads to an increase of essential preventive vaccination value and premium vaccine improvement which is currently insufficient and has a limited value of creation, 3) industrialization and globalization of vaccines to overcome insufficient investment caused by the small scale of the do mestic market while high cost and long time are required to develop them, and 4) strategic plan for consumers with the help of World Health Organization (WHO), Global Alliance for Vaccines and Immunization (GAVI), and International Vaccine Fund enter the global market [6] . The vaccine indus try is becoming an emerging attractive industry. There are four opportunity factors. 1) vaccines have less failure and re quire less cost than synthetic drugs in the field of drug devel opment and have more chances to enter the global market, 2) the global vaccine market scale is expanding in quantity, 3) as a new concept, the clinic oriented vaccines are growing in development and in the mar ket, 4) there is an improvement of value added vaccines development techniques with con temporary growth of biome dicines and technical progress of biotechnology/nanotechnology and so on [6] .
In conclusion, the scale of the pharmaceutical industry in Korea and the vaccine product output and portion in the in dustry were described. Vaccines have a significant portion as the 10th ranked drug in the classification of whole complete preparated drugs. Also, vaccines classified by each item were observed in market scale in terms of essential and general
